153 related articles for article (PubMed ID: 35123285)
1. Prognostic Impact of Pathology, Cytoreduction, and Tumor Markers in Pseudomyxoma Peritonei.
Lopes A; de Mello ES; Mendoza Lopez RV; Leonardi PC; Ribeiro U
J Surg Res; 2022 Jun; 274():68-76. PubMed ID: 35123285
[TBL] [Abstract][Full Text] [Related]
2. Factors influencing long-term survival after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei originating from appendiceal neoplasms.
van Eden WJ; Kok NFM; Snaebjornsson P; Jóźwiak K; Woensdregt K; Bottenberg PD; Boot H; Aalbers AGJ
BJS Open; 2019 Jun; 3(3):376-386. PubMed ID: 31183454
[TBL] [Abstract][Full Text] [Related]
3. Pre-operative tumour marker status predicts recurrence and survival after complete cytoreduction and hyperthermic intraperitoneal chemotherapy for appendiceal Pseudomyxoma Peritonei: Analysis of 519 patients.
Taflampas P; Dayal S; Chandrakumaran K; Mohamed F; Cecil TD; Moran BJ
Eur J Surg Oncol; 2014 May; 40(5):515-520. PubMed ID: 24462284
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of baseline and serial carcinoembryonic antigen and carbohydrate antigen 19.9 measurements in patients with pseudomyxoma peritonei treated with cytoreduction and hyperthermic intraperitoneal chemotherapy.
van Ruth S; Hart AA; Bonfrer JM; Verwaal VJ; Zoetmulder FA
Ann Surg Oncol; 2002 Dec; 9(10):961-7. PubMed ID: 12464587
[TBL] [Abstract][Full Text] [Related]
5. Complete Cytoreductive Surgery vs. Debulking Surgery for pseudomyxoma peritonei of appendiceal origin: A propensity score-matched study based on a single-center experience.
Ma R; Lu D; Wang B; Zhai X; Xia A; An L; Shi G; Cai Y; Lu Y; Pang S; Chen F; Xu H
Eur J Surg Oncol; 2021 Sep; 47(9):2369-2376. PubMed ID: 34034942
[TBL] [Abstract][Full Text] [Related]
6. Prognostic Significance of Preoperative Tumor Markers in Pseudomyxoma Peritonei from Low-Grade Appendiceal Mucinous Neoplasm: a Study from the US HIPEC Collaborative.
Nizam W; Fackche N; Pessoa B; Kubi B; Cloyd JM; Grotz T; Fournier K; Dineen S; Veerapong J; Baumgartner JM; Clarke C; Patel SH; Wilson GC; Lambert L; Abbott DE; Vande Walle KA; Lee B; Raoof M; Maithel SK; Russell MC; Zaidi MY; Johnston FM; Greer JB
J Gastrointest Surg; 2022 Feb; 26(2):414-424. PubMed ID: 34506026
[TBL] [Abstract][Full Text] [Related]
7. Elevated tumour markers are normalized in most patients with pseudomyxoma peritonei 7 days after complete tumour removal.
Di Fabio F; Aston W; Mohamed F; Chandrakumaran K; Cecil T; Moran B
Colorectal Dis; 2015 Aug; 17(8):698-703. PubMed ID: 25704482
[TBL] [Abstract][Full Text] [Related]
8. Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in pseudomyxoma peritonei of appendiceal origin: result of a single centre study.
Di Leo A; Corvasce A; Weindelmayer J; Mason EJ; Casella F; de Manzoni G
Updates Surg; 2020 Dec; 72(4):1207-1212. PubMed ID: 32410159
[TBL] [Abstract][Full Text] [Related]
9. Advanced Pseudomyxoma Peritonei Requiring Gastrectomy to Achieve Complete Cytoreduction Results in Good Long-Term Oncologic Outcomes.
Di Fabio F; Mehta A; Chandrakumaran K; Mohamed F; Cecil T; Moran B
Ann Surg Oncol; 2016 Dec; 23(13):4316-4321. PubMed ID: 27380645
[TBL] [Abstract][Full Text] [Related]
10. Complete cytoreduction for pseudomyxoma peritonei is optimal but maximal tumor debulking may be beneficial in patients in whom complete tumor removal cannot be achieved.
Dayal S; Taflampas P; Riss S; Chandrakumaran K; Cecil TD; Mohamed F; Moran BJ
Dis Colon Rectum; 2013 Dec; 56(12):1366-72. PubMed ID: 24201390
[TBL] [Abstract][Full Text] [Related]
11. The modified Glasgow prognosis score predicts for overall and disease-free survival following cytoreductive surgery and HIPEC in patients with pseudomyxoma peritonei of appendiceal origin.
Tan GH; Novo CA; Dayal S; Chandrakumaran K; Mohamed F; Cecil T; Moran BJ
Eur J Surg Oncol; 2017 Feb; 43(2):388-394. PubMed ID: 27866811
[TBL] [Abstract][Full Text] [Related]
12. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei of appendicular and extra-appendicular origin.
Delhorme JB; Severac F; Averous G; Glehen O; Passot G; Bakrin N; Marchal F; Pocard M; Lo Dico R; Eveno C; Carrere S; Sgarbura O; Quenet F; Ferron G; Goéré D; Brigand C;
Br J Surg; 2018 May; 105(6):668-676. PubMed ID: 29412465
[TBL] [Abstract][Full Text] [Related]
13. Impact of Cellularity on Oncologic Outcomes Following Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemoperfusion for Pseudomyxoma Peritonei.
Choudry HA; Pai RK; Shuai Y; Ramalingam L; Jones HL; Pingpank JF; Ahrendt SS; Holtzman MP; Zureikat AH; Zeh HJ; Bartlett DL
Ann Surg Oncol; 2018 Jan; 25(1):76-82. PubMed ID: 29110275
[TBL] [Abstract][Full Text] [Related]
14. Mode of Presentation in 1070 Patients With Perforated Epithelial Appendiceal Tumors, Predominantly with Pseudomyxoma Peritonei.
Shariff US; Chandrakumaran K; Dayal S; Mohamed F; Cecil TD; Moran BJ
Dis Colon Rectum; 2020 Sep; 63(9):1257-1264. PubMed ID: 33216496
[TBL] [Abstract][Full Text] [Related]
15. Serum and ascites tumor markers in the diagnostic and prognostic prediction for appendiceal pseudomyxoma peritonei.
Wang B; Ma R; Rao B; Xu H
BMC Cancer; 2023 Jan; 23(1):90. PubMed ID: 36703100
[TBL] [Abstract][Full Text] [Related]
16. Pseudomyxoma peritonei: clinical pathological and biological prognostic factors in patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC).
Baratti D; Kusamura S; Nonaka D; Langer M; Andreola S; Favaro M; Gavazzi C; Laterza B; Deraco M
Ann Surg Oncol; 2008 Feb; 15(2):526-34. PubMed ID: 18043976
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic performance of positron emission tomography in the staging of pseudomyxoma peritonei.
Flood MP; Kong JC; Pham T; Waters PS; Soucisse M; Ramsay R; Wong HL; Mitchell C; Michael M; McCormick JJ; Warrier SK; Akhurst T; Heriot AG
Eur J Surg Oncol; 2022 Jul; 48(7):1606-1613. PubMed ID: 35148916
[TBL] [Abstract][Full Text] [Related]
18. Analysis of the characteristics and outcomes of patients with pseudomyxoma peritonei of appendiceal origin treated with curative-intent surgery.
Kamada Y; Hida K; Yonemura Y; Nakakura A; Kitai T; Mizumoto A; Yoshida S; Tokoro Y; Obama K
Surg Oncol; 2023 Dec; 51():102012. PubMed ID: 37972508
[TBL] [Abstract][Full Text] [Related]
19. Clinical findings of patients with pseudomyxoma peritonei of appendiceal origin undergoing Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC).
Iavazzo C; Spiliotis J
Updates Surg; 2020 Sep; 72(3):923-924. PubMed ID: 32602012
[No Abstract] [Full Text] [Related]
20. Surveillance of Low-Grade Appendiceal Mucinous Neoplasms With Peritoneal Metastases After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: Are 5 Years Enough? A Multisite Experience.
Solomon D; Bekhor E; Leigh N; Maniar YM; Totin L; Hofstedt M; Aycart SN; Carr J; Ballentine S; Magge DR; Golas BJ; Pai RK; Polydorides AD; Bartlett DL; Labow DM; Choudry HA; Sarpel U
Ann Surg Oncol; 2020 Jan; 27(1):147-153. PubMed ID: 31385130
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
